Marshall Edwards, Inc.'s NV-128, a Novel mTOR Inhibitor, Demonstrates Good Safety Profile and High Anti-Cancer Activity In Vivo SYDNEY, AUSTRALIA and NEW CANAAN, CT--(Marketwire - September 29, 2009) - Marshall Edwards, Inc. (NASDAQ: MSHL), a pharmaceutical company specializing in clinical development of oncology drugs, today...

Independent Data Monitoring Committee Reviews Marshall Edwards, Inc.'s Arrangements for Data Analysis of the Ovature Trial NEW CANAAN, CT--(Marketwire - June 17, 2009) - The Independent Data Monitoring Committee (IDMC) created to oversee the conduct of the Phase III OVArian TUmor REsponse (OVATURE) Trial, which convened...

Board Changes at Novogen Limited Announced NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - March 23, 2009) - Novogen Limited (ASX: NRT) (NASDAQ: NVGN) is pleased to announce the appointment of Mr. William D. Rueckert to its Board of...

Marshall Edwards, Inc. Granted IND for Triphendiol NEW CANAAN, CT--(Marketwire - January 7, 2009) - Marshall Edwards, Inc. (NASDAQ: MSHL) today announced that it has been granted an Investigative New Drug (IND) approval by the United States Food and...

Marshall Edwards' Phenoxodiol and Novogen's NV-128 Display Divergent Mechanisms of Action but Potent Synergistic Anti-Cancer Activity When Used in Combination NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - October 30, 2008) - Pre-clinical studies presented at the 9th International Conference on Membrane Redox Systems in Wellington New Zealand this...